Display options
Cite
de la Monte SM, Volicer L, Hauser SL, et al. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1992;32(6):733-42doi: 10.1002/ana.410320606.
de la Monte, S. M., Volicer, L., Hauser, S. L., & Wands, J. R. (1992). Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease. Annals of neurology, 32(6), 733-42. https://doi.org/10.1002/ana.410320606
de la Monte, S M, et al. "Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease." Annals of neurology vol. 32,6 (1992): 733-42. doi: https://doi.org/10.1002/ana.410320606
de la Monte SM, Volicer L, Hauser SL, Wands JR. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1992 Dec;32(6):733-42. doi: 10.1002/ana.410320606. PMID: 1471863.
Copy Download .nbib Format: NLM
Share it on
Full text links
Wiley

Ann Neurol. 1992 Dec;32(6):733-42. doi: 10.1002/ana.410320606.

Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease.

Annals of neurology

S M de la Monte, L Volicer, S L Hauser, J R Wands

Affiliations

  1. Department of Neuropathology, Massachusetts General Hospital, Harvard Medical School, Boston.

PMID: 1471863 DOI: 10.1002/ana.410320606

Abstract

Neuronal thread protein is a recently characterized, approximately 20-kd protein that accumulates in brains with Alzheimer's disease (AD) lesions. This study examined whether concentrations of neuronal thread protein (NTP) were also increased in the cerebrospinal fluid (CSF) of individuals with probable (clinically diagnosed) and definite (histopathologically proved) AD. Using a highly sensitive three-site monoclonal antibody-based immunoradiometric assay, we measured NTP concentrations in CSF from 84 patients with probable AD and mild dementia (duration, 4.05 +/- 0.36 years), 45 with Parkinson's disease and minimal or no dementia (duration, 4.73 +/- 0.78 years), 73 with multiple sclerosis, and 73 nondemented control subjects. NTP concentrations were also measured in postmortem ventricular fluid and temporal lobe neocortex extracts from 31 subjects with histopathologically proved AD and 14 age-matched control subjects. The mean concentration of NTP in the CSF was higher in AD (4.15 +/- 0.25 ng/ml; 95% confidence interval [CI] limits, 3.65-4.65) than in Parkinson's disease (1.96 +/- 0.16 ng/ml; 95% CI, 1.65-2.27), multiple sclerosis (1.6 +/- 0.14 ng/ml; 95% CI limits, 1.33-1.88), or control subjects (1.27 +/- 0.06 ng/ml; 95% CI limits, 1.15-1.40) (p < 0.001). In addition, 70% of the patients with probable AD had concentrations of NTP in CSF that were higher than 2.5 ng/ml (> upper 99% CI limit in the control group), compared with 23% of Parkinson's disease patients, 11% of multiple sclerosis patients, and 4% of control subjects. The mean concentrations of NTP in the ventricular fluid and brain tissue from individuals with documented AD and end-stage dementia were threefold higher than the levels detected in the CSF from the remaining patients with probable AD and mild dementia. Moreover, of 9 patients with AD, postmortem brain and CSF manifested 5- to 50-fold higher levels of NTP compared with the CSF samples obtained an average of 6 years earlier. These findings demonstrate that NTP levels are elevated in the CSF of individuals with AD and that NTP levels in the CSF increase strikingly with progression of dementia and neuronal degeneration.

Similar articles

Quinn JF, Harris C, Kaye JA, Lind B, Carter R, Anekonda T, Ralle M.
Int J Alzheimers Dis. 2011;2011:150916. doi: 10.4061/2011/150916. Epub 2011 Oct 19.
PMID: 22028982

Show all 15 similar articles

Cited by

Substances

MeSH terms

Publication Types

Grant support

LinkOut - more resources